Basal cell carcinoma is the most common form of cutaneous cancer. In majority of cases it is locally invasive with slow growth, ranging in size from a couple of milimeters to a couple of centimeters and located primarily on sunexposed regions. Giant basal cell carcinoma, defined as a tumor that is larger than 5 cm in diameter, is a very rare type of cutaneous malignancy accounting for 0.5-1% of all basal cell carcinomas. We present a case of a 74-yearold man with a 17 x 14 cm giant basal cell carcinoma in the right supraclavicular region. Detailed history revealed that the lesion had started as a papule 15 years before presentation. Despite its growth, the lesion was neglected until admission. Histological examination of skin lesion confirmed superficial and focally infiltrative types of basal cell carcinoma. Electron radiotherapy was administered with 54 Gy total dose delivered in 20 daily fractions which resulted in healing of lesions and adequate response. Thus, definitive radiotherapy can be just as effective as excision when the criteria are met.
Introduction
Basal cell carcinoma (BCC) is the most common form of cutaneous cancer. Most cases are locally invasive, indolent, characterized by slow growth, rare metastasis, located predominantly on ultraviolet (UV) exposed areas such as the head and neck (in 80-85% of cases) and on the trunk (roughly only 10%) (1) . Caucasians over the age of 40 are the most affected group (2) . The majority of BCCs range from a couple of millimeters to a couple of centimeters (mean size of 11.7mm ± 5.9 mm), with surgical excision being the preferred method of treatment leading to a 5-year cure rate of 95% (3) . In rare instances, basal cell carcinomas can be larger in size leading to a potentially more aggressive clinical course and difficulties in opting for the appropriate therapeutic modality. According to the American Joint Committee on Cancer, tumors with a diameter larger than 5 cm are defined as Giant Basal Cell Carcinoma (GBCC) (4) . The incidence of this rare variant has been reported to be 0.5% -1% (5) . Some authors think that a diameter greater than 10 cm should be the cutoff value for GBCC (6) . When the maximum diameter is more than 20 cm, the term Super Giant Basal Cell Carcinoma can be used and, to the best of our knowledge, there are only 10 reported cases in the literature (7, 8) .
Case Report
We report a case of a 74-year-old male with an extensive histopathologically verified basal cell carcinoma that slowly progressed over the course of 15 years on the right supraclavicular region of the shoulder. The lesion started in 2003 as an erythematous papule that was neglected for many years. The patient was examined for the first time in 2008 when he was diagnosed to have a suspicious basal cell carcinoma and/or discoid erythematous lupus and he was treated with local corticosteroids, antibiotics and 5% fluorouracil cream with no improvement. The lesion was afterwards biopsied and histopathologic examination confirmed superficial type of basal cell carcinoma; however, further When the patient was presented to the Oncology and Radiology skin and soft tissue specialist committee, his lesion was found to be inoperable and radiotherapy was indicated. The patient was treated with electron radiotherapy consisting of a total dose (TD) of 54 Gy delivered in 20 daily fractions (2.5 Gy/ fraction), with appropriate margins over the course of 20 days. The radiotherapy resulted in resolution of ulcerations and lesion spreading, leading to contraction of the residual paler erythematous plaque, post-irradiation telangiectasias and the surrounding white halo-like borders (Figure 3) .
After 6 months post-radiotherapy follow up, two biopsies were taken and histopathology revealed post radiation fibrosis with no elements of BCC.
Discussion
Giant basal cell carcinoma is a rare variant of non-melanoma skin cancer with an epidemiological profile being Caucasian, male gender, and a peak occurrence in the seventh decade. The reported sites of predilection, by a slim margin, were the back (27.5%) and face (23.5%) with the upper extremities amounting to 13.7%. Rarer cases have been reported on the abdominal wall, genital region, anterior trunk, and lower extremity. One clinicopathological study and Clinically, GBCC has been reported as the following subtypes: nodular-ulcerative (10), vegetant/exophytic (11), extensively ulcerative (12), morpheaform (13) , and polypoid (14) . Naturally, they are more likely to invade the extradermal structures due to their size and years of growth, thus potentially causing cosmetic deformations. Invasion of the underlying cartilage, soft tissue, and bone was not seen in our patient during the workup.
In terms of histology, there are differences between conventional sized BCCs and GBCCs. Purnell et al. published a review of 57 cases comparing the histological differences contributing to excessive growth. Besides size, GBCCs were thicker, with higher incidence of ulcerations, and possessed a more infiltrative growth than conventional BCC, but the authors concluded that histological features alone were unlikely to be the reason for the large clinical size (15) . Up to 27 histological subtypes of basal cell carcinoma have been reported (16) . The histological subtype is an important factor that leads to the progression and formation of GBCCs, and they can be broadly categorized as non-aggressive and aggressive. Non-aggressive one includes superficial and nodular, while aggressive GBCC includes metatypical, micronodular and morpheaform subtypes. Archontaki et al. reported that 54% of GBCCs reviewed were histologically nodular, 19% infiltrating, 9.5% were metatypical or morpheaform, and only 4.76% were accounted as superficial spreading (9) . On the other hand, in a study of 50 patients with GBCC by Randle et al., 72% were classified as infiltrative or micronodular. Finally, the World Health Organization (WHO) classification, currently in use, only recognizes the following subtypes: nodular, superficial, micronodular, infiltrating, sclerosing/morphoeic, basosquamous, pigmented, BCC with sarcomatoid differentiation, BCC with adnexal differentiation, and fibroepithelial, which leads to improved clarity and reproducibility (17) .
Metastasis is a rare complication of conventional, mostly indolent, BCC as it spreads more horizontally rather than vertically. According to the literature, there have been roughly 300 cases reported (18) , with an estimated incidence rate of 0.0028% to 0.5% (19, 20) . Mean time interval from tumor onset to metastasis is roughly 9 years and only half of the patients survive 8 months after the beginning of metastatic symptoms (21) . In a published review, Randle et al., concluded that BCCs larger than 2 cm in diameter, located on the ear or mid face, with aggressive histopathological type, previous treatment and, history of neglect or radiation have a higher propensity for potential metastasis (22) . A positive correlation of the tumor size and metastatic potential has been established. Tumors larger than 3 cm, 5cm and 10 cm in diameter increase the incidence of metastasis to 2%, 25%, 50% respectively (23) . All of these factors apply to GBCC making it essential to rule out metastasis in patients. In fact, most cases of metastatic BCCs are in fact GBCC. Archontaki et al. reported that metastasis was present in 17.6% of GBCC patients during the primary examination (9) . Contrary to the general belief, multiple studies have confirmed that there is no correlation between specific histopathological subtype of BCC with a high- er incidence of metastasis (24) . The most common sites of metastasis are lymph nodes, lung and bone, but there are individual documented cases of hematogenous spread to other organs. Despite a detailed work-up, we did not find any signs of metastasis in our patient.
There are no specific guidelines for treating GBCC or metastatic disease. Wide surgical excision with free margins remains the preferred treatment of choice for GBCC, as well as for BCC. In general, BCCs less than 1 cm implement margins 2-4 mm achieving a 5-year cure rate of 95% (3). Larger lesions require clinical margins of 3-5 mm due to subclinical extension. Other potential treatment options include immunomodulators (25) , topical chemotherapeutic agents (25) , photodynamic therapy (26) , biological therapy (Vismodegib, a sonic hedgehog pathway inhibitor, FDA approved in advanced cases and metastasis, 150 mg once daily) (8), Mohs micrographic surgery, and radiotherapy, whether definitive or adjuvant. In general, surgery and radiotherapy are the most effective treatment options (27) . The risk of tumor residue in GBCC post excision has been reported to be 68% (13) . When the tumor is inoperable or surgery is contraindicated in an elderly patient, as it was in our patient, radiotherapy is an appropriate alternative. In general, radiotherapy can be administered by using linear accelerators for high-energy X-rays, or by electron radiotherapy (regularly preferred due to the accurate prescription of used energy for depth of penetration) for many clinical applications including GBCC. There is a high degree of variation in fractionation regimes in non-melanoma skin cancers. According to one survey done in the United Kingdom (UK), the four most common regimes used were (18-20 Gy in 1 fraction, 35 Gy in 5 fractions, 45 Gy in 10 fractions and 55 Gy in 20 fractions) (28) . Other dosing fractions suggested in literature are included in Table 1 . Guidelines for BCC state 0.5 cm deep margins and lateral margins to be 0.5 cm (morphoeic, large, infiltrative or poorly defined require 0.7cm-1cm) with an additional 0.5 to 1cm for electron therapy to account for penumbra of electrons (30) . Factors and tumor specificities indicating radiotherapy as the treatment option are presented in Table 2 . There is a correlation between greater tumor size and depth, with a decrease in local cure rates. Regular followup is required since currently there are no guidelines suggesting when to take a control biopsy to rule out post radiotherapy BCC recurrence. Early detection and adequate, timely treatment remain imperative in preventing recurrence and metastasis.
Conclusion
Giant basal cell carcinoma is a rare subtype of BCC that requires a thorough work up and can lead to difficulties in choosing the appropriate treatment. Patient awareness needs to be increased as timely medical consultation is essential for the treatment success. When the criteria are met, definitive radiotherapy can be just as effective and therefore it is an adequate alternative to surgical excision. Since there is a lack of guidelines for GBCC treatment criteria, follow up and radiotherapy dose fractionation schedules, they should be provided as soon as possible.
